The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated ...

Significant associations for semaglutide initiation included being female, using certain medication classes including antidepressants, and being covered by a point-of-service plan. (HealthDay News ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

Addressing these inequities is crucial to reducing the obesity burden. The current study sought to explore the factors that control semaglutide initiation among obese adults without diabetes and ...